| Page 12 | Kisaco Research
  • Demystifying product-market fit in the context of digital health, where clinical need, usability, and reimbursement must align.
  • Identifying key indicators—user adoption, engagement, and outcomes—that show readiness to scale.
  • Strategies for translating validated need into scalable, sustainable digital health solutions.
Innovation and Investment
  • Discuss strategies for trial design that account for hormonal fluctuations, comorbidities, and age-related variables unique to the menopausal transition.
  • Highlight regulatory, industry, and advocacy efforts that are pushing for menopause-specific representation in therapeutic areas beyond just women’s health.
  • Sharing advancements to educate clinical trial patients about menopause.
Menopause and Longevity
Drug Development
 

Johan van Hylckama

CSO
Freya Biosciences

Johan van Hylckama

CSO
Freya Biosciences

Johan van Hylckama

CSO
Freya Biosciences
  • Expanding access to mammograms and diagnostics in underserved communities.
  • Personalizing Risk Assessment & Early Detection, how AI, genetic testing, and targeted outreach are improving outcomes.
  • The adoption of innovation in breast & cervical cancer screening centred around patient centricity.
Oncology
Digital Health
  • How the demand for menopause-focused functional foods, probiotics, and supplements is shaping new business opportunities.
  • Sharing insights into how nutrition and food as medicine links bone, heart, and brain health in menopause and the opportunity to address these health outcomes through wellness.
  • Expanding access to menopause nutrition solutions through pharmacies, e-commerce, consumer wellness, and employer plans.
Menopause and Longevity
Nutrition and Food as Medicine

Author:

Jacqueline Oliveira-Cella

Founder
wellBe Consulting

Jacqueline Oliveira-Cella

Founder
wellBe Consulting

Author:

Laura Katz

CEO
Helaina

Laura Katz

CEO
Helaina
 

Laura Katz

CEO
Helaina

Laura Katz

CEO
Helaina

Laura Katz

CEO
Helaina

Demonstrate how AI-driven initiatives - like predictive modelling and automated inspection -translate into measurable outcomes (e.g., defect reduction, shorter batch release cycles) that justify capital investment and cross-functional prioritization

 

Miller Morris

CEO
Comma

Miller Morris

CEO
Comma

Miller Morris

CEO
Comma
  • Leveraging tech and epidemiological data to reduce diagnostic delays in reproductive health.
  • Exploring AI, biomarkers, digital therapeutics, and digital platforms that enable earlier and more accurate diagnoses.
  • Advice to start-ups and sharing the market opportunity for clinical integration in preventative & diagnostic women’s health.
Reproductive Health
Digital Health

Author:

Miller Morris

CEO
Comma

Miller Morris

CEO
Comma